Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 7,949 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $7.95, for a total value of $63,194.55. Following the completion of the sale, the insider now directly owns 213,695 shares in the company, valued at $1,698,875.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Aduro BioTech Inc (NASDAQ ADRO) traded down $0.40 during trading hours on Tuesday, hitting $6.75. The stock had a trading volume of 536,713 shares, compared to its average volume of 404,640. Aduro BioTech Inc has a 52-week low of $6.01 and a 52-week high of $14.05. The stock has a market cap of $521.80 and a price-to-earnings ratio of -4.96.
Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). The business had revenue of $3.79 million during the quarter, compared to analysts’ expectations of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.54) EPS. equities research analysts expect that Aduro BioTech Inc will post -1.28 EPS for the current year.
Several equities analysts recently issued reports on ADRO shares. BidaskClub cut Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. HC Wainwright set a $10.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Tuesday. Canaccord Genuity set a $30.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Thursday, December 14th. Oppenheimer set a $15.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Monday, December 11th. Finally, William Blair reissued an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $17.71.
Institutional investors have recently modified their holdings of the company. Legal & General Group Plc grew its position in shares of Aduro BioTech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 1,043 shares in the last quarter. Fox Run Management L.L.C. bought a new position in shares of Aduro BioTech in the 3rd quarter valued at about $127,000. SG Americas Securities LLC bought a new position in shares of Aduro BioTech in the 3rd quarter valued at about $167,000. Trexquant Investment LP bought a new position in shares of Aduro BioTech in the 3rd quarter valued at about $175,000. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Aduro BioTech by 2,294.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 24,420 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 23,400 shares during the last quarter. Hedge funds and other institutional investors own 45.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/16/insider-selling-aduro-biotech-inc-adro-insider-sells-7949-shares-of-stock.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.